Time-restricted eating for patients with moderate chronic kidney disease
Time-restricted Eating in Patients With Moderate Chronic Kidney Disease and Albuminuria: A Pilot Randomized, Open-label, Double-arm Trial (TRECK)
This study tests if following a 12-hour eating schedule can help people with moderate chronic kidney disease improve their kidney function and lose weight.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Geneva Academic / other |
| Locations | 1 site (Geneva) |
| Trial ID | NCT06618859 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effects of time-restricted eating (TRE) on proteinuria, glomerular filtration rate decline, and weight loss in patients with moderate chronic kidney disease (CKD) and albuminuria. Participants will follow a 12-hour eating window, and their dietary habits will be monitored using a smartphone app. The goal is to understand how this dietary approach can impact the progression of CKD and improve metabolic health in affected individuals.
Who should consider this trial
Good fit: Ideal candidates are adults with moderate chronic kidney disease (KDIGO stage G2 and G3) and albuminuria, who can adhere to the study's dietary requirements.
Not a fit: Patients with uncontrolled hypertension, diabetes with hypoglycemia, or those on specific restrictive diets may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved management of chronic kidney disease and better patient outcomes.
How similar studies have performed: While the approach of time-restricted eating is relatively novel in the context of CKD, preliminary studies suggest dietary interventions can positively influence metabolic health.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Clinical criteria * Adult men and women * Chronic Kidney Disease with KDIGO stage G2 and G3 defined by a Glomerular Filtration Rate between 30 and 90 mL/min/1.73m2 * Albuminuria stage A2 or A3, but without nephrotic-range proteinuria: 3 to 200 mg/mmol * Body mass index 18-40 kg/m2 * Eating window of 12 hours (self-reported and measured during the run-in phase) * Study-related criteria * Able to give informed consent and follow the study procedures for the entire duration * Confident use of a smartphone compatible with the MyFoodRepo app (iOS, Android) and able to take regular pictures of food/drinks Exclusion Criteria: * Clinical criteria * Pregnant and breastfeeding women, plans for maternity during the study * Eating disorder(s) * Other diets: low-carb, ketogenic diet, hypocaloric diets (eviction for food intolerances, vegan/vegetarian diet are not excluded) * Uncontrolled blood pressure (\> 160/100 mmHg) * Diabetes with hypoglycemic drug(s) will be excluded, however those with impaired glucose tolerance (prediabetes, as defined by the American Diabetes Association) or diabetes with no risk of hypoglycemia (i.e. treated with non-hypoglycemic drugs or without medication) will be included * Oral corticosteroids * Uncontrolled diabetes HbA1c \> 8.5% * Active cancer and/or oncologic treatment over the previous 12 months * Major mental illness * Consumption of \> 7 standard units of alcohol per week for women and \> 14 standard units of alcohol per week for men * Shift work, such as evening shifts or night shifts planned during the study * Travel/trip to a different time zone (≥ 2-hour time difference) planned during the study * Study-related criteria and other interventions * Recent treatment modification in the last 3 months, including but not limited to ACE blockers, SLGT2i, finerenone * Patients with recent glomerulonephritis diagnosis on more than 2 immunosuppressive drugs * Patients with kidney transplant in the last past year * Enrolled in another interventional clinical trial (medication, medical device) over the previous 1 month and planned during the study
Where this trial is running
Geneva
- University Hospital, Geneva — Geneva, Switzerland (Recruiting)
Study contacts
- Principal investigator: Sophie de Seigneux, MD, PhD — University Hospital, Geneva
- Study coordinator: Delal Dalga, MD, PhD
- Email: delal.dalga@unige.ch
- Phone: +41-22-3723311
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.